"The voice for cancer physicians and their patients in Massachusetts."

  • 29 Jun 2018 8:16 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved nivolumab and ipilimumab (Opdivo and Yervoy; Bristol-Myers Squibb) in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma. Read full press release. 

  • 29 Jun 2018 8:01 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved everolimus tablets for oral suspension (Afinitor Disperz; Novartis) for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. Everolimus is also approved for two other manifestations of TSC. TSC associated subependymal giant cell astrocytoma (SEGA) and TSC-associated renal angiomyolipoma. Read full press release.

  • 29 Jun 2018 7:48 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved brentuximab vedotin (Adcentris; Seattle Genomics) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Read full press release. 

  • 17 Apr 2018 2:00 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administrator approved everoliums tablets for oral suspension (Afinitor Disperz; Novartis Pharmaceuticals) for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. Everolimus is also approved for two other manifestations of TSC: TSC-associated subependymal giant cell astrocytoma (SEGA) and TSC-associated renal angiomyolipoma. Read full press release.

  • 17 Apr 2018 1:52 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted approvals to nivolumab (Opdivo; Bristol-Myers Squibb) and ipilimumab (Yervoy; Bristol-Myers Squibb) in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma. Read full press release. 

  • 27 Feb 2018 1:44 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved durvalumab (Infinzi; AstraZeneca) for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Read full press release

  • 27 Feb 2018 11:54 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved abermacicib (Verzeno; Eli Lilly) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Read full press release. 

  • 15 Feb 2018 9:18 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved apalutamide (Erleada; Janssen) for patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). Read full press release. 

  • 08 Feb 2018 2:12 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved abiraterone acetate (Zytiga, Janssen Biotech, Inc.) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC). Read full press release.

  • 12 Jan 2018 1:20 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to olaparib tablets (Lynparza; AstraZeneca) a poly (ADP-ribose) polymerase (PARP) inhibitor, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Read full press release. 

Upcoming events

  • No upcoming events

Massachusetts Society of Clinical Oncologists (c)

P.O. Box 549154, Waltham, MA, 02454
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software